JNJ · News · 20261022N

Electrophysiology Product Roadmap

JOHNSON & JOHNSON · 2026-10-22 · Importance 23 · Surprise 24

Johnson & Johnson reported VARIPURE study data for the VARIPULSE Pro Platform in European patients undergoing atrial-fibrillation ablation. The platform achieved 100% acute procedural success, a 0.4% primary adverse-event rate, and a 17.9-minute mean ablation time. The investigational OMNYPULSE Platform produced 82.5% freedom from documented atrial-arrhythmia recurrence at 12 months under stringent monitoring. VARIPULSE Pro is not approved in the United States, while the OMNYPULSE findings support continued development of J&J’s pulsed-field-ablation portfolio.

Key facts

• VARIPULSE Pro Catheter is not approved in the U.S. source
• Johnson & Johnson presented new data from the late-breaking VARIPURE and Omny-IRE studies at the Asia Pacific Heart Rhythm Society (APHRS) 2026 Annual Meeting in Busan, South Korea. source
• VARIPULSE findings reported 100% acute procedural success with the VARIPULSE Pro Platform. source
• VARIPULSE findings reported a 0.4% primary adverse event rate and a mean ablation time of 17.9 minutes with the VARIPULSE Pro Platform. source
• Omny-IRE data showed 82.5% of patients treated with the investigational OMNYPULSE Platform remained free from documented atrial arrhythmia recurrence at 12 months under stringent monitoring. source
• The VARIPURE and Omny-IRE studies were published simultaneously in Europace and Heart Rhythm. source